Sasaki Y, Fujita S, Yoshioka H, Takimoto C, Mitsutani N, Koizumi T
Gan To Kagaku Ryoho. 1982 May;9(5):898-905.
The characteristic of a slow infusion technique of angiography provided a new method of selective intraarterial administration. We named this new method "high pressure one hot injection." When we tried to apply this method to patients with inoperable hepatoma, we considered that Neocarzinostatin (NCS) was a very applicable antitumor drug in terms of cell killing kinetics. Fifteen patients with inoperable hepatoma were treated with NCS by the selective intra-hepatic arterial infusion method. Administration of NCS was given by using a technique of high pressure one shot injection. The administration dose of NCS was 6000u. or 10000u., and 10 patients received once, and the others twice or three times. Results were as follows: 1) According to both Karnofsky's criteria and the criteria of direct response for solid cancer, an objective response was observed in 6 patients (40%). In proportion to the increase of the total dose and frequencies the individual efficacy increased. 2) The median survival was 5.5 months. 3) Decrease of serum AFP was seen, prominently within one month after injection. 4) The major side effects were fever (93%), liver dysfunctions (53%), leukopenia (46%), thrombocytopenia (33.3%), and their frequencies were related to the dose of one injection and that of the total. These results suggest that the high pressure one shot injection of NCS is very effective to inoperable hepatoma, but both dose and interval of injection remain to discussed.
血管造影缓慢输注技术的特点提供了一种选择性动脉内给药的新方法。我们将这种新方法命名为“高压单次注射”。当我们试图将这种方法应用于无法手术的肝癌患者时，我们认为从细胞杀伤动力学角度来看，新制癌菌素（NCS）是一种非常适用的抗肿瘤药物。15例无法手术的肝癌患者采用选择性肝动脉内输注法用NCS进行治疗。NCS的给药采用高压单次注射技术。NCS的给药剂量为6000单位或10000单位，10例患者接受一次给药，其他患者接受两次或三次给药。结果如下：1）根据卡诺夫斯基标准和实体癌直接反应标准，6例患者（40%）观察到客观反应。随着总剂量和给药次数的增加，个体疗效提高。2）中位生存期为5.5个月。3）观察到血清甲胎蛋白下降，在注射后1个月内尤为明显。4）主要副作用为发热（93%）、肝功能障碍（53%）、白细胞减少（46%）、血小板减少（33.3%），其发生率与单次注射剂量和总剂量有关。这些结果表明，NCS高压单次注射对无法手术的肝癌非常有效，但注射剂量和间隔仍有待探讨。
